The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes.

Trial Profile

The Effect of Liraglutide Adjunct to Insulin on Glucagon Response to Hypoglycaemia in Subjects With Type 1 Diabetes.

Completed
Phase of Trial: Phase I

Latest Information Update: 10 Feb 2017

At a glance

  • Drugs Liraglutide (Primary) ; Insulin
  • Indications Type 1 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms LATIN T1D
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 01 Nov 2016 Results (n=40) summarizing pharmacokinetic endpoints derived from the steady-state concentration-time curves for liraglutide 0.6, 1.2, and 1.8 mg in Type 1 Diabetes Mellitus, published in the Clinical Pharmacokinetics Journal.
    • 09 Jun 2016 Results of steady-state pharmacokinetic data (n=40) published in the Clinical Pharmacokinetics
    • 24 Sep 2013 Primary endpoint results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top